Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
Voyager Therapeutics announced that its tau-targeted gene therapy VY1706 will be featured in a late-breaking poster presentation at the Alzheimer's Association International Conference (AAIC) in July. The presentation will cover IND-enabling GLP non-human primate study data, demonstrating a favorable tolerability profile up to the highest dose tested and tau protein reduction of up to 75% in relevant brain regions.
Key figures
- Drug Name
- VY1706
- Tau reduction
- up to 75%
- Max dose tested
- 5E13 vg/kg
- Dosing start timeline
- second half of 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.